2021
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionSerum insulin levelsCancer survivorsLoss interventionPercent body fatSerum levelsSerum biomarkersTissue biomarkersBody compositionMonth 6Insulin levelsBreast tissueBreast cancerInsulin receptorBody fatStage I breast cancerBreast tissue levelsI breast cancerWeight loss trialBreast tissue markersLevels of CD163Breast tissue biopsiesUsual careLifestyle intervention
2020
MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression.
Han R, Zhao J, Lu L. MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression. Oncology Reports 2020, 43: 2062-2072. PMID: 32186770, DOI: 10.3892/or.2020.7549.Peer-Reviewed Original ResearchConceptsBreast cancerNormal breast tissueMDA-MB-231 cellsPatient survivalT-47DKaplan-Meier survival curvesBreast tissueCancer-associated mortalityLonger survival timeCommon cancer typesExpression levelsReverse transcription-quantitative PCRPotential therapeutic toolBreast cancer invasionMicroRNA-34a expressionTranscription-quantitative PCRTumor cell proliferationOverall survivalUnderlying molecular mechanismsCaspase-3 activityDownregulation of E2F1Clinical managementExpression of E2F1Survival timeClinical relevance